Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus

References

• International Diabetes Federation. Diabetes Atlas, 6th edn. Available at: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf [Last accessed 7 August 2014]
   Google Scholar
• Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
   PubMed Web of Science ®Google Scholar
• Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8
   PubMed Web of Science ®Google Scholar
• Kang HW, Kim DJ, Lee MS, et al. Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjects. Diabetes Res Clin Pract 2005;69:180-7
   PubMed Web of Science ®Google Scholar
• Kim DJ, Lee MS, Kim KW, et al. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 2001;50:590-3
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fukushima M, Usami M, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 2003;26:1211-15
   PubMed Web of Science ®Google Scholar
• Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev 2011;27:79-84
   PubMed Web of Science ®Google Scholar
• Sheu WH, Rosman A, Mithal A, et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: an Asian-Pacific perspective and expert recommendations. Diabetes Res Clin Pract 2011;92:312-21
   PubMed Web of Science ®Google Scholar
• Luk A, Chan JC. Diabetic nephropathy – what are the unmet needs? Diabetes Res Clin Pract 2008;82(Suppl 1):S15-20
   PubMedGoogle Scholar
• Mu YM, Misra A, Adam JM, et al. Managing diabetes in Asia: overcoming obstacles and the role of DPP-IV inhibitors. Diabetes Res Clin Pract 2012;95:179-88
   PubMed Web of Science ®Google Scholar
• Chan SP, Ji LN, Nitiyanant W, et al. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific – real-life effectiveness and care patterns of diabetes management: the RECAP-DM study. Diabetes Res Clin Pract 2010;89:e30-2
   PubMedGoogle Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. Diabetes Care 2009;32(Suppl 2):S322-5
   Google Scholar
• Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
   PubMed Web of Science ®Google Scholar
• Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
   PubMed Web of Science ®Google Scholar
• Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14:348-57
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
   PubMed Web of Science ®Google Scholar
• Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-61
   PubMed Web of Science ®Google Scholar
• Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352-61
   PubMed Web of Science ®Google Scholar
• Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:833-43
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Rosenstock J, Durán-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care 2013;36:3875-81
   PubMed Web of Science ®Google Scholar
• Kozlovski P, Foley J, Shao Q, et al. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes 2013;4:151-6
   Google Scholar
• Kothny W, Foley J, Kozlovski P, et al. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-7
   PubMed Web of Science ®Google Scholar
• Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:364-71
   PubMed Web of Science ®Google Scholar
• Zeng Z, Yang J, Tong N, et al. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin 2013;29:921-9
   PubMed Web of Science ®Google Scholar
• Zeng Z, Choi DS, Mohan V, et al. Linagliptin is efficacious and well tolerated in Asian patients with inadequately controlled type 2 diabetes. Diabetes 2012;61:A300
   Google Scholar
• Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41
   PubMed Web of Science ®Google Scholar
• Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:737-44
   PubMed Web of Science ®Google Scholar
• Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-16
   PubMed Web of Science ®Google Scholar
• Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 2012;4:227-37
   PubMed Web of Science ®Google Scholar
• Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28:268-75
   PubMed Web of Science ®Google Scholar
• Yang W, Pan CY, Tou C, et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011;94:217-24
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009;32(Suppl 2):S253-9
   PubMed Web of Science ®Google Scholar
• Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-43
   PubMed Web of Science ®Google Scholar
• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
   PubMed Web of Science ®Google Scholar